Literature DB >> 21431347

Successful immunosuppressive and iron chelation therapy for a severe aplastic anemia patient undergoing hemodialysis due to chronic renal failure.

Junji Hiraga1, Reona Sakemura2, Hiroshi Yamashita3, Toshimitsu Suzuki4, Satoshi Kitagawa5, Yasunari Takakuwa6, Shinichi Mizuno2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21431347     DOI： 10.1007/s12185-011-0816-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

Review 1.  Development of tridentate iron chelators: from desferrithiocin to ICL670.

Authors:  Hanspeter Nick; Pierre Acklin; René Lattmann; Peter Buehlmayer; Suzanne Hauffe; Joachim Schupp; Daniele Alberti
Journal:  Curr Med Chem       Date:  2003-06       Impact factor: 4.530

2.  Remission induction in a patient with severe aplastic anemia and renal failure by immunosuppressive treatment including antithymocyte globulin.

Authors:  H G Hartmann; H W Pees; G A Jutzler; P G Scheurlen
Journal:  Blut       Date:  1982-10

3.  Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.

Authors:  S J Rosenfeld; J Kimball; D Vining; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

Review 4.  Long-term efficacy and safety of deferasirox.

Authors:  Maria Domenica Cappellini
Journal:  Blood Rev       Date:  2008-12       Impact factor: 8.250

5.  Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.

Authors:  Bushra Yusuf; Peter McPhedran; Ursula C Brewster
Journal:  Am J Kidney Dis       Date:  2008-06-05       Impact factor: 8.860

6.  Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.

Authors:  F Wimazal; T Nösslinger; C Baumgartner; W R Sperr; M Pfeilstöcker; P Valent
Journal:  Eur J Clin Invest       Date:  2009-05       Impact factor: 4.686

7.  Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.

Authors:  Norbert Frickhofen; Hermann Heimpel; Joachim P Kaltwasser; Hubert Schrezenmeier
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

Review 8.  Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.

Authors:  Takahiro Suzuki; Masao Tomonaga; Yasushi Miyazaki; Shinji Nakao; Kazuma Ohyashiki; Itaru Matsumura; Yutaka Kohgo; Yoshiro Niitsu; Seiji Kojima; Keiya Ozawa
Journal:  Int J Hematol       Date:  2008-06-27       Impact factor: 2.490

9.  A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.

Authors:  Keisuke Miyazawa; Kazuma Ohyashiki; Akio Urabe; Tomoko Hata; Shinji Nakao; Keiya Ozawa; Takayuki Ishikawa; Junji Kato; Yoichi Tatsumi; Hiraku Mori; Midori Kondo; Junsuke Taniguchi; Hiromi Tanii; Lisa Rojkjaer; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2008-07-04       Impact factor: 2.319
  9 in total
  3 in total

1.  Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease.

Authors:  Ashok Raj; Kerry McGowan; Esther Knapp; Jun Zhao; Siddharth Shah
Journal:  Cureus       Date:  2022-04-14

2.  Challenges of caring for an advanced chronic kidney disease patient with severe thrombocytopenia.

Authors:  Tetsu Akimoto; Chiharu Ito; Atsushi Kotoda; Manabu Ogura; Taro Sugase; Ryuta Sato; Eiji Kusano; Daisuke Nagata
Journal:  Clin Med Insights Case Rep       Date:  2013-11-25

3.  Successful sirolimus therapy of an aplastic anemia patient with chronic kidney disease: A case report.

Authors:  Haiyue Niu; Weiwei Qi; Yihao Wang; Limin Xing; Rong Fu; Zonghong Shao; Huaquan Wang
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.